Drug intelligence / Profile preview

Aurufluxx

Development stage: Unknown
Lead developer: Ruhrpharm
Modality: Small Molecules
Administration: Oral

Overview

Aurufluxx is a phytopharmaceutical developed by Ruhrpharm, containing a dry extract of goldenrod (Solidago virgaurea). It is primarily indicated for the treatment of inflammatory diseases of the lower urinary tract and as a flushing therapy for the prevention and treatment of urinary stones and kidney gravel. The extract exerts its therapeutic effects through a combination of diuretic (aquaretic), anti-inflammatory, and mild antispasmodic properties. While the exact molecular targets are not fully characterized, the efficacy is attributed to secondary plant metabolites such as flavonoids, saponins, and phenolic acids found in the goldenrod plant. It is an approved medication in Germany.

Brand names: Aurufluxx
Other names: goldenrod extractSolidago virgaurea extractEchte Goldrute-Trockenextrakt

Beyond the preview

Go deeper on Aurufluxx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurufluxx.

Explore the full profile